This document is scheduled to be published in the Federal Register on 10/17/2012 and available online at http://federalregister.gov/a/2012-25434, and on FDsys.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended

(5 U.S.C. App), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in

sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as

patentable materials, and personal information concerning individuals associated with the

grant applications, the disclosure of which would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

R25 Review

Date: October 30, 2012

Time: 11:00 AM to 12:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

1

Contact Person: Gerald L. McLaughlin, Ph.D.

Scientific Review Officer Office of Extramural Affairs

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-402-6626 gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Synthesis and Preclinical Evaluation of Medications to Treat

Substance Use Disorders (SUDS) (R01)

Date: November 1, 2012

Time: 9:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

Contact Person: Gerald L. McLaughlin, Ph.D.

Scientific Review Officer Office of Extramural Affairs

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-402-6626 gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

The Diversity-promoting Institutions Drug Abuse Research

Program (DIDARP)

Date: November 15, 2012

Time: 2:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place:	National Institutes of Health Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852 (Telephone Conference Call)
Contact Person:	Nadine Rogers, Ph.D. Scientific Review Officer Office of Extramural Affairs National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4229, MSC 9550 Bethesda, MD 20892-9550 301-402-2105 rogersn2@nida.nih.gov
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)	
Dated: October 11, 2012	
Michelle Trout, Program Analyst Office of Federal Advisory Committee Policy	

[FR Doc. 2012-25434 Filed 10/16/2012 at 8:45 am; Publication Date: 10/17/2012]